Summary
The possible polymorphism of the glucuronidation reaction in man has been investigated using two hypolipidaemic compounds, fenofibrate and clofibrate, as the test probes.
The formation of fenofibryl and clofibryl glucuronides was identified by their susceptibility to hydrolyses by β-glucuronidase. The urinary excretion of the glucuronides was measured in 72 healthy volunteers after a single dose of fenofibrate, and in 104 subjects given a single dose of clofibric acid.
Fenofibrate was excreted at a lower rate than clofibrate, since 13.94% and 26.55% of the doses of fenofibrate and clofibrate respectively, were recovered in urine in 8 h. Correlation analysis indicated that sex and body mass index significantly influenced the formation of fenofibryl glucuronide, whereas age and oral contraceptives affected the excretion of clofibryl acid glucuronide. The 8-hour urinary excretion patterns of clofibryl glucuronide and of clofibric acid presented a Gaussian distribution, whereas those of fenofibryl glucuronide and fenofibric acid showed 2 populations. When the metabolic ratio free fenofibric acid/glucuronide was considered, 84.7% of subjects presented the ratio 0.147, and 15.3% had the 3-fold higher ratio of 0.421.
The study has shown, in the human population studied, that the glucuronidation of fenofibric acid but not that of clofibric acid may present a polymorphism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cayen MN, Ferdinandi ES, Greselin E, Robinson WJ, Dvornik D (1977) Clofibrate and clofibric acid: comparison of the metabolic disposition in rats and dogs. J Pharmacol Exp Ther 200: 33–43
Gugler R (1978) Clinical pharmacokinetics of hypolipidemic drugs. Clin Pharmacokinet 3: 425–439
Elsom LF, Hawkins DR, Chasseaud LF (1976) Identification of a major metabolite of the new hypolipidaemic agent, isopropyl 2-[4′(p-chlorobenzoyl)phenoxy]-2-methylpropionate (procetofen) in humans by gas chromatography-mass spectrometry. J Chromatogr 123: 463–467
Kritchevsky D (1980) Pharmacologie du fénofibrate. Nouv Presse Médicale 9: 3769–3773
Baldwin JR, Witiak PT, Feller DR (1980) Disposition of clofibrate in the rat — acute and chronic administration. Biochem Pharmacol 29: 3143–3154
Emudianughe TS, Caldwell J, Sinclair KA, Smith RL (1983) Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man. Drug Metab Disposit 11: 97–102
Steiner E, Iselius L, Alvan G, Lindsten J, Sjöqvist I (1985) A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 38: 394–401
Weber WW (1985) N-Acetylation Pharmacogenetics: Notes and Comments on Acetylator Status, Drug Toxicity and Disease, In: Siest G (ed) Drug metabolism — molecular approaches and pharmacological implication. Pergamon, Paris, pp 5–9
Berk P (1980) The distribution of serum bilirubin levels in man — implications for the diagnosis of Gilbert's syndrome. In: Okolicsanyi L (ed) Familial hyper-bilirubinemia. John Wiley and Sons, New York, pp 7–19
Liu HF, Leroy P, Nicolas A, Magdalou J, Siest G (1989) Evaluation of a versatile reversed-phase high-performance liquid chromatographic system using cethexonium bromide as ionpairing reagent for the analysis of glucuronic acid conjugates. J Chromatogr 493: 137–147
Schroeder A (1976) Analyse d'un mélange de distribution de probabilité de même type. Rev Stat Appl 24: 1–39
Cazes P (1976) Décomposition d'un histogramme en composantes gaussiennes. Rev Stat Appl 24: 63–82
Sadlej-Sosnowska N (1987) Determination of glycyrrhizinic and glycyrrhetinic acids in pharmaceuticals by high-performance liquid chromatography. J Pharm Biomed Anal 5: 289–293
Trautman KH, Haefelfinger P (1981) Determination of the cephalosporin Ro 13-9904 in plasma, urine and bile by means of ion-pair reversed phase chromatography. J High Resolut Chromatogr Commun 4: 54–59
Siest G, Antoine B, Fournel S, Magdalou J, Thomassin J (1987) The glucuronosyltransferases: what progress can pharmacologists expect from molecular biology and cellular enzymology? Biochem Pharmacol 36: 983–989
Gautam A, Seiligson H, Gordon ER, Seiligson D, Boyer JL (1984) Irreversible binding of conjugated bilirubin to albumin in cholestatic rats. J Clin Invest 73: 873–877
Van Breemen RB, Fenselau C (1985) Acylation of albumin by 1-O-acylglucuronides. Drug Metab Disposit 13: 318–320
Ruelius HW, Kirkman SK, Young EM, Janssen FW (1986) Reactions of oxaprozin-1-O-acyl glucuronide in solutions of human plasma and albumin. Adv Exp Med Biol 197: 431–441
Van Breemen RB, Fenselau C (1986) Reaction of bilirubin glucuronides with serum albumin. J Chromatogr 383: 387–392
Well DS, Janssen FW, Ruelius HW (1987) Interactions between oxaprozin glucuronide and human serum albumin. Xenobiotica 17: 1437–1449
Faed EM, McQueen EG (1978) Separation of two conjugates of clofibric acid (CPIB) found in the urine of subjects taking clofibrate. Clin Exp Pharmacol Physiol 5: 195–198
Stogniew M, Fenselau C (1982) Electrophilic reactions of acyl-linked glucuronides. Formation of clofibrate mercapturate in humans. Drug Metab Dispos 10: 609–613
Reddy IK, Azarnoff DL, Hignite DE (1980) Hypolipidaemic hepatic peroxisome proliferators form — a novel class of chemical carcinogens. Nature (London) 283: 397–398
Committee of Principal Investigators (1978) A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 40: 1069–1118
Caldwell J, Weil A, Sinclair KA (1987) Acylation of amino acids and other endobiotics by xenobitoic carboxylic acids. In: Gorrod JW, Oehlschlager H, Caldwell J (eds) Metabolism of Xenobiotics. Taylor and Francis, London, pp 217–224
Blane GF, Pinaroli F (1980) Fenofibrate: études de toxicologie animale en rapport avec les effets secondaires chez les malades. Nouv Presse Med 9: 3737–3746
Weil A, Caldwell J, Strolin-Benedetti M (1990) The metabolism and disposition of 14C-Fenofibrate in human volunteers. Drug Metab Disposit 18: 115–120
Desager JP, Harvengt C (1978) Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers. Int J Clin Pharmacol 16: 570–574
Miners JO, Attwood J, Birkett DJ (1983) Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br J Clin Pharmacol 16: 503–509
Mitchell MC, Hanew T, Meredith CG, Schenker S (1983) Effects of oral contraceptive steroids on acetaminophen metabolism and elimination. Clin Pharmacol Ther 34: 48–53
Okonek M, Dittmann M, Bock KW (1987) Paracetamol conjugation: influence of oral contraceptives, old age and liver disease. Naunyn Schmiedebergs Arch Pharmacol 335: 415
Schillings RT, Schrader SR, Ruelius HW (1971) Urinary metabolites of lorazepam in humans and four animal species. Arzneim Forsch 21: 1059–1065
Sisenwine SF, Tio CO, Schrader SR et al. (1972) The biotransformation of oxazepam in man, miniature swine and rat. Arzneim Forsch 22: 632–637
Fleischmann R, Stärz U, Remmer H (1985) Increased activity of certain isozenzymes of cytochrome P-450 and UDP-glucuronyltransferases in the liver of cigarette smokers. In: Matern S, Bock KW, Gerok W (eds) Advances in glucuronide conjugation. MTP Press Limited, Hingham USA, pp 351–356
Chapman MJ (1987) Pharmacology of fenofibrate. Am J Med 83 (5B): 21–25
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Liu, H.F., Vincent-Viry, M., Galteau, M.M. et al. Urinary glucuronide excretion of fenofibric and clofibric acid glucuronides in man. Is it polymorphic?. Eur J Clin Pharmacol 41, 153–159 (1991). https://doi.org/10.1007/BF00265909
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00265909